Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Cachexia and Cancer

How Oral GLP-1 Drugs Work For Weight Loss

Does Cinnamon Help with Weight Loss?

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Mental Health Disorders, Weight Gain, and Exercise

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

How Does Semaglutide Work to Lose Weight?

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Unexplained Weight Loss: When It Might Signal a Health Problem

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

See more featured articles »

Circadian Rhythm and Weight Loss

Weight Loss After Bariatric Surgery

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Vegetarian Diets for Weight Loss

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Cachexia / Wasting Syndrome

Military Diet: Health Risks

The Natural Molecule That Could Rival Ozempic

Semaglutide and Weight Loss in Menopause

Wegovy: A Breakthrough in Weight Loss?

Latest Weight Loss News and Research

Lost weight is less likely to return when exercise follows obesity treatment

A systematic review and meta-analysis of 11 randomized controlled trials found that exercise during the post-weight-loss maintenance phase reduced weight regain by an average of 2.81 kg compared with control groups. Evidence for fat-mass reduction remained inconclusive, highlighting the need for longer, standardized trials with better adherence and body-composition monitoring.

24 Jun 2026

Strength training plus cardio cuts type 2 diabetes risk the most

A 20-year prospective cohort study of 143,715 US healthcare professionals found that long-term resistance training was associated with a substantially lower risk of type 2 diabetes. The lowest risk was seen among participants who combined regular resistance training with adequate aerobic activity and limited TV viewing.

23 Jun 2026

Circadian rhythm influences calorie burning after eating

Han-Chow Koh, PhD, and Frank A.J.L. Scheer, PhD, of the Medical Chronobiology Program at the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine, are the co-lead and senior author, respectively, of a paper published in Metabolism, "Constant-routine protocol reveals an endogenous circadian rhythm in diet-induced thermogenesis with a peak in the biological morning."

23 Jun 2026

Researchers trace soaring poison control calls to semaglutide approval for weight loss

When semaglutide's popularity exploded following FDA approval for weight management in 2021, so too did a wave of calls to poison control centers.

23 Jun 2026

Hyperemesis gravidarum increases risks for pregnancy and birth complications

Pregnant women with a severe form of nausea face increased risks for several pregnancy and birth complications, according to a new Stanford Medicine study of 2.5 million California births.

22 Jun 2026

GLP-1 medications may lower risk of multiple substance use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

21 Jun 2026

AI discovers hidden antibiotic candidates inside disease-causing prions

New antibiotic candidates for drug-resistant bacteria may reside inside prions, mis-folded protein in the brain best known for rare and fatal degenerative brain diseases.

19 Jun 2026

Experts outline a multidisciplinary approach to managing clinical obesity

The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment.

17 Jun 2026

GLP-1 medications may reduce violent behavior in adults

The use of GLP-1 medications commonly prescribed for weight loss or managing diabetes may have effects that extend beyond metabolic health, including on behaviors linked to violence, according to Rutgers researchers.

17 Jun 2026

Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug.

16 Jun 2026

Study identifies top predictors for weight loss using tirzepatide

One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

GLP-1 therapy associated with more dizziness and fainting

Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications.

14 Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Novel metal-free prodrug suppresses cancer spread in preclinical models

A carefully designed metal-free carbon monoxide prodrug may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine.

12 Jun 2026

Single-dose vaccine provides complete protection against Andes hantavirus

In a study published in The Lancet, researchers at The University of Texas Medical Branch (UTMB) report the development of new vaccines that, in animal testing, provided full protection against the deadly Andes hantavirus after a single dose.

11 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Elevated blood pressure linked to lower dementia risk in people with physical frailty

For people with physical frailty, having high blood pressure may be associated with a lower risk of dementia, according to a study published on June 10, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

10 Jun 2026

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Injectable semaglutide may improve fertility outcomes in PMOS

Researchers at the University of Colorado Anschutz have published a proof-of-concept study in Fertility and Sterility demonstrating that injectable semaglutide may offer meaningful reproductive benefits for women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS).

9 Jun 2026